GlassScriptPhysician profile
Elizabeth A Stamper
NPI 1548467111
$1,549.45
in general payments reported to CMS, 2019-2025
26 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $187 · 2021: $118 · 2022: $191 · 2023: $168 · 2024: $368 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $290.47 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $223.71 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $118.30 | 2022-2025 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $104.12 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.69 | 2021-2025 | Jardiance |
| Dexcom, INC. | $91.91 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $74.38 | 2024-2025 | Freestyle Libre 3 |
| Pfizer INC. | $71.09 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $57.16 | 2022-2023 | Eliquis |
| Medtronic, INC. | $51.42 | 2024 | Intellis Adaptivestim |
| Amgen INC. | $50.38 | 2024-2025 | Evenity, Repatha, Otezla |
| Boston Scientific Corporation | $36.07 | 2020 | |
| Ardelyx, INC. | $32.73 | 2024-2025 | Ibsrela |
| Sunovion Pharmaceuticals INC. | $31.43 | 2022 | |
| Exact Sciences Corporation | $29.85 | 2024-2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.19 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.11 | 2022 | |
| Eisai INC. | $19.39 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.23 | 2021 | |
| Kyowa Kirin, INC. | $17.83 | 2025 | |
| Astellas Pharma US INC | $17.62 | 2025 | Veozah |
| Axsome Therapeutics, INC. | $17.08 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.27 | 2024 | Xifaxan |
| Akcea Therapeutics, INC. | $15.15 | 2020 | |
| Allergan, INC. | $11.41 | 2020 | |
| Endogastric Solutions, INC | $8.46 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Stamper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.